Literature DB >> 24965074

Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.

N Teich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24965074     DOI： 10.1007/s10151-014-1192-2

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN： 1123-6337            Impact factor:   3.781


× No keyword cloud information.
  5 in total

1.  Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis.

Authors:  Niels Teich; Tobias Klugmann
Journal:  J Crohns Colitis       Date:  2013-06-28       Impact factor: 9.071

2.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

3.  Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds.

Authors:  Markus Streit; Zsuzsanna Beleznay; Lasse R Braathen
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

4.  Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers--correlations to healing status.

Authors:  H J Wallace; M C Stacey
Journal:  J Invest Dermatol       Date:  1998-03       Impact factor: 8.551

Review 5.  Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy.

Authors:  Angelo V Marzano; Alessandro Borghi; Antoni Stadnicki; Carlo Crosti; Massimo Cugno
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325
  5 in total
  2 in total

1.  Systematic review: medical therapy for fibrostenosing Crohn's disease.

Authors:  Cathy Lu; Brandon Baraty; Helen Lee Robertson; Alexis Filyk; Hua Shen; Tak Fung; Kerri Novak; Christopher Ma; Remo Panaccione; Jean-Paul Achkar; Sara El Ouali; David Bruining; Vipul Jairath; Brian Feagan; Florian Rieder
Journal:  Aliment Pharmacol Ther       Date:  2020-05-13       Impact factor: 8.171

2.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.